INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 267 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $21,376,002 | +33.8% | 312,104 | +35.2% | 0.01% | 0.0% |
Q1 2024 | $15,978,972 | +4.1% | 230,910 | +7.8% | 0.01% | 0.0% |
Q4 2023 | $15,346,806 | +40.3% | 214,281 | +2.1% | 0.01% | +20.0% |
Q3 2023 | $10,935,514 | -1.6% | 209,935 | +2.3% | 0.01% | 0.0% |
Q2 2023 | $11,117,645 | 0.0% | 205,312 | 0.0% | 0.01% | 0.0% |
Q1 2023 | $11,117,645 | +4.7% | 205,312 | +2.3% | 0.01% | -16.7% |
Q4 2022 | $10,621,731 | -99.9% | 200,713 | +8.0% | 0.01% | +20.0% |
Q3 2022 | $8,646,763,000 | -37.3% | 185,832 | -23.1% | 0.01% | -28.6% |
Q2 2022 | $13,784,877,000 | -8.9% | 241,501 | -2.3% | 0.01% | +16.7% |
Q1 2022 | $15,128,246,000 | +294.9% | 247,234 | +237.8% | 0.01% | +500.0% |
Q4 2021 | $3,831,080,000 | +22.7% | 73,196 | -12.6% | 0.00% | 0.0% |
Q3 2021 | $3,122,051,000 | -4.3% | 83,746 | +4.8% | 0.00% | 0.0% |
Q2 2021 | $3,261,558,000 | +43.0% | 79,901 | +18.9% | 0.00% | 0.0% |
Q1 2021 | $2,280,367,000 | +6.0% | 67,208 | -0.6% | 0.00% | 0.0% |
Q4 2020 | $2,151,079,000 | +62.1% | 67,644 | +30.8% | 0.00% | 0.0% |
Q3 2020 | $1,326,674,000 | +10.9% | 51,702 | +11.0% | 0.00% | 0.0% |
Q2 2020 | $1,195,915,000 | +67.2% | 46,588 | +0.1% | 0.00% | 0.0% |
Q1 2020 | $715,365,000 | -46.0% | 46,543 | +20.5% | 0.00% | 0.0% |
Q4 2019 | $1,324,812,000 | +337.0% | 38,613 | -4.8% | 0.00% | – |
Q3 2019 | $303,140,000 | -25.8% | 40,581 | +29.0% | 0.00% | – |
Q2 2019 | $408,403,000 | +10.6% | 31,464 | +3.8% | 0.00% | – |
Q1 2019 | $369,298,000 | +120.6% | 30,320 | +106.3% | 0.00% | – |
Q4 2018 | $167,433,000 | -47.5% | 14,700 | 0.0% | 0.00% | – |
Q3 2018 | $318,990,000 | +22.8% | 14,700 | 0.0% | 0.00% | – |
Q2 2018 | $259,749,000 | -16.1% | 14,700 | 0.0% | 0.00% | – |
Q1 2018 | $309,435,000 | +45.4% | 14,700 | 0.0% | 0.00% | – |
Q4 2017 | $212,856,000 | +77021.7% | 14,700 | -18.8% | 0.00% | – |
Q3 2016 | $276,000 | -60.7% | 18,100 | 0.0% | 0.00% | -100.0% |
Q2 2016 | $703,000 | +39.8% | 18,100 | 0.0% | 0.00% | 0.0% |
Q1 2016 | $503,000 | -55.5% | 18,100 | -13.9% | 0.00% | 0.0% |
Q4 2015 | $1,131,000 | +128.0% | 21,011 | +69.4% | 0.00% | 0.0% |
Q3 2015 | $496,000 | +80.4% | 12,400 | +44.2% | 0.00% | – |
Q2 2015 | $275,000 | – | 8,600 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |